Zimhi™ (naloxone) – New drug approval
October 18, 2021 - Adamis Pharmaceuticals announced the FDA approval of Zimhi (naloxone), in adults and pediatric patients, for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
Download PDF
